Cart
sales@molnova.com
TETRAHYDROPIPERINE
CAS No. 23434-88-0
TETRAHYDROPIPERINE( Cosmoperine )
Catalog No. M20421 CAS No. 23434-88-0
TETRAHYDROPIPERINE is a natural product derived from piperine can be used to treat convulsion epilepsy relieve pain and control insects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 33 | In Stock |
|
| 50MG | 48 | In Stock |
|
| 100MG | 68 | In Stock |
|
| 200MG | 99 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTETRAHYDROPIPERINE
-
NoteResearch use only, not for human use.
-
Brief DescriptionTETRAHYDROPIPERINE is a natural product derived from piperine can be used to treat convulsion epilepsy relieve pain and control insects.
-
DescriptionTETRAHYDROPIPERINE is a natural product derived from piperine can be used to treat convulsion epilepsy relieve pain and control insects.
-
In Vitro——
-
In Vivo——
-
SynonymsCosmoperine
-
PathwayMembrane Transporter/Ion Channel
-
TargetTRP/TRPV Channel
-
RecptorHtrpv1|CYP450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number23434-88-0
-
Formula Weight289.37
-
Molecular FormulaC17H23NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO:57 mg/mL (196.97 mM)
-
SMILESO=C(CCCCc1ccc2OCOc2c1)N1CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Edwin Andrés Correa H?Gest?Tt E D Sterner O et al. In vitro TRPV1 activity of piperine derived amides[J]. Bioorganic & Medicinal Chemistry 2010 18(9):3299-3306.
molnova catalog
related products
-
SET 2
SET 2 is an antagonist of transient receptor potential vanilloid type 2(TRPV2) with an IC50 of 0.46 μM. SET 2 shows selectivity over TRPV1, TRPV3 and TRPV4.
-
Vitexin
Vitexin protects brain against cerebral I/R injury, and this effect may be regulated by mitogen-activated protein kinase (MAPK) and apoptosis signaling pathways.
-
CIM0216
CIM0216 is a synthetic TRPM3 activator whose potency and apparent affinity greatly exceeds that of the canonical TRPM3 agonist.
